Brokerages predict that Illumina, Inc. (NASDAQ:ILMN) will report sales of $870.91 million for the current fiscal quarter, Zacks reports. Six analysts have issued estimates for Illumina’s earnings. The lowest sales estimate is $867.23 million and the highest is $874.77 million. Illumina reported sales of $853.00 million in the same quarter last year, which indicates a positive year-over-year growth rate of 2.1%. The business is scheduled to announce its next earnings report on Tuesday, October 22nd.
According to Zacks, analysts expect that Illumina will report full-year sales of $3.52 billion for the current financial year, with estimates ranging from $3.46 billion to $3.54 billion. For the next fiscal year, analysts forecast that the firm will report sales of $4.03 billion, with estimates ranging from $3.93 billion to $4.12 billion. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that cover Illumina.
Illumina (NASDAQ:ILMN) last posted its earnings results on Monday, July 29th. The life sciences company reported $1.35 earnings per share for the quarter, topping analysts’ consensus estimates of $1.32 by $0.03. Illumina had a net margin of 27.56% and a return on equity of 21.73%. The firm had revenue of $838.00 million for the quarter, compared to the consensus estimate of $835.12 million. During the same period in the previous year, the firm posted $1.43 EPS. The business’s quarterly revenue was up 1.0% on a year-over-year basis.
ILMN stock opened at $285.07 on Monday. The stock has a market cap of $42.68 billion, a PE ratio of 49.84, a PEG ratio of 2.71 and a beta of 1.10. The company has a debt-to-equity ratio of 0.42, a quick ratio of 6.10 and a current ratio of 6.79. Illumina has a 12 month low of $268.62 and a 12 month high of $380.76. The business’s 50-day moving average price is $321.15.
In other Illumina news, SVP Robert P. Ragusa sold 2,230 shares of the company’s stock in a transaction that occurred on Thursday, August 8th. The shares were sold at an average price of $293.09, for a total transaction of $653,590.70. Following the transaction, the senior vice president now owns 10,685 shares in the company, valued at approximately $3,131,666.65. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Jay T. Flatley sold 3,300 shares of the company’s stock in a transaction that occurred on Wednesday, May 22nd. The shares were sold at an average price of $304.44, for a total transaction of $1,004,652.00. Following the transaction, the director now owns 282,516 shares in the company, valued at approximately $86,009,171.04. The disclosure for this sale can be found here. Insiders have sold a total of 50,458 shares of company stock worth $16,527,618 in the last 90 days. 0.38% of the stock is currently owned by company insiders.
Institutional investors have recently modified their holdings of the business. First Manhattan Co. boosted its holdings in shares of Illumina by 18.8% in the 1st quarter. First Manhattan Co. now owns 3,464 shares of the life sciences company’s stock valued at $1,076,000 after acquiring an additional 547 shares during the last quarter. Ardevora Asset Management LLP boosted its holdings in shares of Illumina by 14.2% in the 1st quarter. Ardevora Asset Management LLP now owns 101,212 shares of the life sciences company’s stock valued at $31,446,000 after acquiring an additional 12,600 shares during the last quarter. Copper Rock Capital Partners LLC purchased a new stake in shares of Illumina in the 2nd quarter valued at $10,888,000. Jupiter Wealth Management LLC purchased a new stake in shares of Illumina in the 1st quarter valued at $387,000. Finally, Shell Asset Management Co. boosted its holdings in shares of Illumina by 5.8% in the 1st quarter. Shell Asset Management Co. now owns 24,863 shares of the life sciences company’s stock valued at $7,725,000 after acquiring an additional 1,369 shares during the last quarter. Institutional investors and hedge funds own 90.95% of the company’s stock.
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.
Featured Article: What type of investment options does a Roth IRA provide?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.